Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1402411-90-8

Post Buying Request

1402411-90-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1402411-90-8 Usage

Description

Bromo-PEG5-azide contain a bromide group and a terminal azide. The bromide (Br) is a very good leaving group for nucleophilic reactions. The azide group can react with alkyne, BCN, DBCO via Click Chemistry to yield a stable triazole linkage. PEG5 spacer increases solubility in aqueous media.

Check Digit Verification of cas no

The CAS Registry Mumber 1402411-90-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,2,4,1 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1402411-90:
(9*1)+(8*4)+(7*0)+(6*2)+(5*4)+(4*1)+(3*1)+(2*9)+(1*0)=98
98 % 10 = 8
So 1402411-90-8 is a valid CAS Registry Number.

1402411-90-8Downstream Products

1402411-90-8Relevant articles and documents

Using an electrical potential to reversibly switch surfaces between two states for dynamically controlling cell adhesion

Ng, Cheuk Chi Albert,Magenau, Astrid,Ngalim, Siti Hawa,Ciampi, Simone,Chockalingham, Muthukumar,Harper, Jason Brian,Gaus, Katharina,Gooding, John Justin

, p. 7706 - 7710 (2012)

Smart surfaces presenting both antifouling molecules with a charged functional group at their distal end, and molecules that are terminated by RGD peptides for cell adhesion, were fabricated and characterized (see picture). By applying potentials of +300 or -300 mV, the surfaces could be dynamically switched to make the peptide accessible or inaccessible to cells. Copyright

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

-

, (2017/08/08)

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1402411-90-8